March 17 (Reuters) - Indian drugmakers Zydus Lifesciences and Lupin have signed a licensing and supply deal on Tuesday to ...

Semaglutide is a GLP-1 receptor agonist used to treat Type 2 Diabetes and, increasingly, for weight management by helping ...

Delivering treatments to someone under the age of 18 is to be outlawed under the legislation.

India, March 17 -- A breakthrough RNA therapy helps the heart protect and heal itself from the damage following the heart ...

CLEVELAND, Ohio — A study by Ohio State University researchers suggests that adding a stellate ganglion block to cognitive processing therapy (CPT) helps military members and veterans recover from ...

Zydus Lifesciences has partnered with Lupin Limited to co-market its innovative Semaglutide Injection, aimed at adults with type 2 diabetes mellitus ...

When detection capabilities lag behind model capabilities, organizations create a structural gap that attackers are ...

Zydus Lifesciences on Tuesday said it has entered into a licensing and supply agreement with Lupin to expand access of diabetes treatment drug Semaglutide Injection (15 mg/3 ml) with patient-friendly ...

The MenB vaccine offers protection against meningococcal group B bacteria, which are a common cause of meningitis in young ...

Shelley says she would never have used the medication if she had known the risk ...

Scientists in Shanghai have developed a potentially groundbreaking treatment for diabetes that targets the root cause of the disease rather than just its symptoms, offering hope for a functional cure.